Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version
Changes to This Summary (01/30/2019)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about the results of several studies that evaluated treatment options and survival outcomes for patients with periosteal osteosarcoma.
Added text to state that in a series of 431 patients, recurrences occurring less than 2 years from diagnosis were also associated with worse outcomes. Added age at initial diagnosis and presence of metastatic disease at diagnosis as prognostic factors for recurrent osteosarcoma and MFH of bone. Also added text to state that the Children's Oncology Group (COG) reported the outcomes of 431 young patients with recurrent osteosarcoma; patients with recurrences in both lung and bone had worse outcomes than did patients with recurrences in lung only (cited Spraker-Perlman et al. as reference 5 and level of evidence 3iiDiv).
Added text about the results of a COG study that reported the outcomes of patients with recurrent osteosarcoma from seven phase II trials (cited Lagmay et al. as reference 15).
Added text about the results of a COG study that reported the outcomes of patients with recurrent osteosarcoma from seven phase II trials.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summaryand PDQ® - NCI's Comprehensive Cancer Database pages.
.png)
No hay comentarios:
Publicar un comentario